The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
ONGENTYS (Maxx Pharma Pty Ltd)
Product name
ONGENTYS
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
222 working days (255)
Active ingredients
opicapone
Registration type
NCE/NBE
Indication
ONGENTYS (hard capsule) is indicated as adjunctive therapy to preparations of levodopa/ DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.